Cisplatin injection for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests injecting cisplatin directly into lung or lymph node tumors for people with stage IV non-small cell lung cancer. It aims to see if this approach is safe and could help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have stage IV non-small cell lung cancer (NSCLC) that has spread or progressed during treatment.
- You have a tumor or lymph node that can be reached with a bronchoscope (EBUS) for injection.
- You are in generally good health with adequate blood counts and liver/kidney function.
- You have not had chemotherapy within the past 14 days or taken an experimental drug in the past 30 days.
- You are not allergic to cisplatin or iodine contrast dye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to give the chemotherapy drug cisplatin—as a dry powder you inhale—for people with stage IV non-small cell lung cancer who have not yet started treatment. The goal is to see if this inhaled form is safe and effective when added to standard immunotherapy or chemotherapy.
This trial studies an anti-cancer gel that delivers cisplatin directly into a head and neck tumor with a single injection. It mainly checks safety and side effects, and also looks for early signs that the tumor responds in people whose cancer is progressing or no longer responds to standard treatment.
This trial tests a combination of two chemotherapy drugs, cisplatin and gemcitabine, for people with certain rare cancers that no longer respond to a type of immunotherapy called PD-1 inhibitors. The goal is to see how well this treatment works and what side effects it may cause.
This trial tests the drug cisplatin in patients with advanced pancreatic cancer that has a specific DNA repair problem called homologous recombination deficiency (HRD). It may offer a new treatment option for those whose cancer has progressed after at least one prior chemotherapy.
This trial checks whether adding cisplatin to standard chemotherapy after surgery helps women with high-risk early-stage breast cancer lower the chance of the cancer coming back. You would be followed to see how well treatment works and whether it is tolerated.
This trial compares two cisplatin dosing schedules (weekly low-dose vs higher dose less often) given alongside radiation for certain head and neck cancers. It’s testing which schedule works well while keeping side effects manageable during planned, curative-intent radiation.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.